S&P Futures
4,150.75-2.75(-0.07%)Dow Futures
33,141.00-14.00(-0.04%)Nasdaq Futures
14,038.50+3.50(+0.02%)
Eagle Pharmaceuticals, Inc. (EGRX)
Chart Events
Performance Outlook
| Previous Close | 43.44 |
| Open | 42.97 |
| Bid | 35.50 x 1100 |
| Ask | 44.44 x 800 |
| Day's Range | 42.20 - 43.71 |
| 52 Week Range | 36.48 - 53.43 |
| Volume | 385,942 |
| Avg. Volume | 111,663 |
| Market Cap | 562.674M |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | 40.42 |
| EPS (TTM) | 1.06 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.33 |
Fair Value
Related Research
- Zacks
New Strong Sell Stocks for June 18th
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
- Business Wire
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
WOODCLIFF LAKE, N.J., Jun 17, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has responded to the Complete Response Letter ("CRL") for its Abbreviated New Drug Application ("ANDA") for vasopressin received from the U.S. Food and Drug Administration ("FDA") in February 2021.
- Newsfile
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX
New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/eagle-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.To view an enhanc
